Benitec Acquires Option from City of Hope to License IP Related to Second HIV Program
October 08, 2009
Benitec Acquires Option from City of Hope to License IP Related to Second HIV Program
The company said it is working with the City of Hope to investigate the vector-based delivery of an anti-HIV RNA cocktail composed of pHIV7, an shRNA targeting an exon in HIV-1 tat/rev, and a Tar decoy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Calimmune Aims for Human Trial of HIV Drug in 2012
March 15, 2012 / Gene Silencing News - Tacere Considers Sale of Company as Pfizer Exercises Option to HCV Program
February 11, 2010 / Gene Silencing News - Genable Receives FDA Orphan Drug Status for Ocular Disease Drug
April 18, 2013 / Gene Silencing News - UC, San Diego Selected as Site for Benitec HCV Drug Trial
April 18, 2013 / Gene Silencing News - Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate
April 11, 2013 / Gene Silencing News